Does Fatty Liver Cause Migraines?

Does fatty liver cause migraines? While fatty liver disease has not been established as a direct cause of migraines, emerging research suggests the two conditions may share common biological pathways, including insulin resistance, chronic inflammation and dyslipidaemia. Fatty liver disease, or hepatic steatosis, occurs when excess fat accumulates in liver cells, while migraines are a complex neurological disorder. Understanding the potential connections between liver health and headache susceptibility can help you make informed decisions and know when to seek medical advice.

Can fatty liver disease actually cause migraines?

Fatty liver disease has not been established as a direct cause of migraines; both conditions share common risk factors such as insulin resistance and inflammation, but no causal link is recognised in NICE or NHS guidance.

Fatty liver disease has not been established as a direct cause of migraines, but emerging research suggests the two conditions may share common biological pathways rather than one causing the other. Fatty liver disease, known medically as hepatic steatosis, occurs when excess fat accumulates in liver cells. It is broadly divided into metabolic dysfunction-associated steatotic liver disease (MASLD, previously termed non-alcoholic fatty liver disease or NAFLD in older UK guidance including NICE NG49) and alcohol-related liver disease. Migraines, by contrast, are a complex neurological disorder characterised by recurrent, often severe headaches, frequently accompanied by nausea, light sensitivity and visual disturbances.

Several observational studies have noted a higher prevalence of migraine among people with MASLD compared with the general population, though this association does not confirm causation. Both conditions are linked to shared risk factors, including insulin resistance, obesity, chronic low-grade inflammation and dyslipidaemia. It is plausible that these underlying metabolic disturbances contribute independently to both conditions, rather than fatty liver directly triggering migraine attacks.

There is no clinical guideline from NICE or the NHS that identifies fatty liver disease as a recognised cause of migraines. NICE guidance on headaches in people over 12 (CG150) and NICE NG49 on NAFLD/MASLD do not describe a causal link between the two conditions. If you experience frequent or severe headaches alongside symptoms that may suggest liver disease, speaking with your GP is the appropriate first step to investigate both concerns properly.

What is the link between liver health and headaches?

Compromised liver health may influence headache susceptibility through systemic inflammation, altered serotonin metabolism and impaired drug processing, though these mechanisms remain under investigation rather than clinically established.

The liver plays a central role in metabolic regulation, detoxification and the processing of hormones and inflammatory mediators, all of which can influence neurological function and headache susceptibility. When liver health is compromised, as in fatty liver disease, these processes may become dysregulated in ways that could affect the frequency or severity of headaches.

One proposed mechanism involves systemic inflammation. Fatty liver disease is associated with elevated levels of pro-inflammatory cytokines, such as tumour necrosis factor-alpha and interleukin-6.^[19][20] These inflammatory signals are also implicated in migraine pathophysiology, where neuroinflammation and sensitisation of pain pathways in the brain play a key role. Insulin resistance, which is closely linked to MASLD, may also affect serotonin metabolism, a neurotransmitter involved in migraine regulation. These are hypotheses supported by preliminary research rather than established clinical facts, and the relationship between liver health and migraines remains an active area of investigation.

The liver is also responsible for metabolising many substances, including medications used to treat migraines. Impaired liver function can alter how these drugs are processed, potentially affecting their efficacy or increasing the risk of side effects. Prescribers and patients should check the relevant Summary of Product Characteristics (SmPC) for hepatic impairment guidance before starting or continuing any migraine treatment. Hormonal imbalances, particularly involving oestrogen, are another area of interest: the liver metabolises oestrogen, and disruption of this process may influence migraine patterns, especially in women who experience hormonally triggered migraines.

Current UK clinical guidance, including NICE CKS Migraine and NICE CG150, does not recommend routine liver investigations solely on the basis of migraine symptoms.

Which symptoms of fatty liver should you watch out for?

Fatty liver disease is often symptomless in early stages; when symptoms occur they include persistent fatigue, upper right abdominal discomfort and nausea, with jaundice and swelling indicating more advanced disease.

Fatty liver disease is often described as a silent condition because most people with early-stage disease experience no noticeable symptoms at all. In many cases, it is discovered incidentally during blood tests or an ultrasound scan carried out for another reason. This makes awareness of the condition and its risk factors particularly important.

Risk factors for fatty liver disease include type 2 diabetes, obesity (particularly central or abdominal weight gain), high cholesterol or triglycerides, insulin resistance and a history of heavy alcohol use.

When symptoms do occur, they may include:

• Persistent fatigue or low energy, which can be difficult to distinguish from other causes

• A dull or aching discomfort in the upper right abdomen, where the liver is located

• Nausea or a general feeling of being unwell

As the condition progresses to more advanced stages, such as metabolic dysfunction-associated steatohepatitis (MASH) or cirrhosis, more pronounced symptoms may develop, including jaundice (yellowing of the skin or whites of the eyes), swelling in the legs or abdomen, and confusion or difficulty concentrating.

Headaches are not a recognised primary symptom of fatty liver disease in standard clinical descriptions, including NHS and NICE NG49 guidance. However, fatigue and general malaise, which are common in liver disease, can lower a person's threshold for headache and may worsen migraine frequency in those already prone to attacks.

If you have known risk factors for fatty liver disease and are also experiencing frequent headaches, it is worth discussing both concerns with your GP. Your GP can arrange appropriate blood tests, including liver function tests and a FIB-4 score (a first-line fibrosis risk assessment tool recommended in NICE NG49), and imaging if indicated.^[1][7] Where FIB-4 results suggest a higher risk of significant fibrosis, further assessment with an enhanced liver fibrosis (ELF) test or referral to hepatology may follow, in line with NICE NG49 and BSG guidance.^[6][1]

What treatments and lifestyle changes can help both conditions?

Lifestyle modification, including weight reduction of 7 to 10 per cent, a Mediterranean diet and regular exercise, is the primary management for MASLD and can also reduce migraine frequency in people with obesity.

There is currently no licensed medication specifically approved for fatty liver disease in the UK, though several are under investigation. This should be verified against MHRA and NICE publications at the time of reading, as the licensing landscape may change. Management of MASLD focuses primarily on lifestyle modification, which has also been shown to benefit migraine frequency and severity in many people. This overlap in management strategies is clinically meaningful.

Key lifestyle changes that may benefit both conditions include:

• Weight reduction: Losing 7 to 10 per cent of body weight has been shown in clinical studies, and is supported by NICE NG49, to significantly reduce liver fat and inflammation.^[1][23] Weight loss is also associated with reduced migraine frequency in people with obesity.

• Dietary improvement: A Mediterranean-style diet, rich in vegetables, wholegrains, lean protein and healthy fats, supports liver health and has been associated with lower migraine burden in some studies.

• Regular physical activity: UK Chief Medical Officers' guidelines, reflected in NHS physical activity guidance, recommend at least 150 minutes of moderate-intensity aerobic activity per week for adults.^[11][12] Exercise improves insulin sensitivity, reduces liver fat and may reduce migraine frequency.

• Alcohol reduction or abstinence: Alcohol is a recognised migraine trigger and directly contributes to liver fat accumulation.

• Blood sugar and cholesterol management: Optimising these through diet, exercise or medication (where prescribed) addresses shared metabolic risk factors.

For migraine specifically, NICE guidance (CG150 and related technology appraisals) supports the use of acute treatments such as triptans and preventive therapies including topiramate, propranolol and amitriptyline, depending on individual circumstances.^[4][5] NICE has also approved CGRP monoclonal antibodies (such as erenumab, fremanezumab and galcanezumab) and onabotulinumtoxinA for chronic migraine in people who meet specific criteria; these are initiated by specialists.^[8][9] Important safety note: topiramate is contraindicated in pregnancy and must not be used without effective contraception in women of childbearing potential. Refer to the MHRA Drug Safety Update on topiramate for full prescribing requirements.

People with liver disease should inform their prescriber, as liver impairment can affect how some medications are metabolised and may influence prescribing decisions; individual SmPCs should be consulted for hepatic impairment guidance. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online consultations, with prescriber review and pharmacist support, as one option among several for accessing healthcare advice.

When should you see a GP about migraines and liver concerns?

See your GP for frequent or disabling migraines not responding to over-the-counter treatment, and seek emergency care immediately for sudden severe headache, jaundice, vomiting blood or confusion.

You should see your GP if you are experiencing frequent or disabling migraines that are not responding to over-the-counter treatments, or are significantly affecting your quality of life. NICE guidance (CG150) recommends that people with frequent migraines are assessed for preventive treatment, and a GP can initiate this or refer to a neurology or specialist headache service where appropriate, for example in cases of diagnostic uncertainty, chronic migraine, or failure or intolerance of multiple preventive treatments.

Headache red flags requiring urgent or same-day assessment

Seek emergency care (call 999 or go to your nearest accident and emergency department) if a headache:

• Comes on suddenly and is extremely severe (sometimes described as a thunderclap headache)

• Is accompanied by a new neurological deficit, such as weakness, speech difficulty or visual loss

• Occurs with fever, neck stiffness or a rash (which may suggest meningitis)

• Follows a head injury

• Is associated with confusion or reduced consciousness

Contact your GP urgently the same day if you develop a new or significantly changed headache pattern and:

• You are over 50 and this is a new type of headache

• You are pregnant or have recently given birth

• You are immunocompromised or have a history of cancer

• You have features that may suggest giant cell arteritis, such as jaw pain on chewing or scalp tenderness

• You have papilloedema (swelling of the optic disc, sometimes noticed as blurred vision)

Regarding liver concerns, contact your GP if you notice:

• Persistent fatigue that has no obvious explanation

• Discomfort or pain in the upper right abdomen

• Yellowing of the skin or eyes (jaundice)

• Unexplained swelling of the abdomen or legs

• Dark urine or pale stools

• Black, tarry stools (melaena) or vomiting blood, which require urgent assessment

If you develop sudden, severe abdominal pain, vomiting blood, melaena or confusion alongside any of the above, call 999 or go to your nearest accident and emergency department immediately.

For non-urgent concerns, contact your GP surgery in the first instance. NHS 111 is available if you need urgent medical advice outside of GP hours but do not require emergency care.

If you are taking any medications for migraine or other conditions and have been told you have liver disease, always inform your prescriber, as dose adjustments may be necessary. Suspected side effects from any medication can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Scientific References

1. Metabolic dysfunction-associated steatotic liver disease (MASLD): assessment and management (NG49) – full guideline PDF.
2. Scope for guideline update (starting 2025) – MASLD (GID-NG10434).
3. Non-alcoholic fatty liver disease (NAFLD).
4. Headaches in over 12s: diagnosis and management (CG150).
5. Headaches in over 12s: diagnosis and management (CG150) – Recommendations chapter.
6. Assessment for advanced liver fibrosis in people with MASLD (NG49 chapter).
7. Metabolic dysfunction-associated steatotic liver disease (NG49) – Recommendations for research.
8. Single Technology Appraisal – Erenumab for preventing migraine (TA682).
9. Technology appraisal – Galcanezumab scope (TA659).
10. Prospective real-world analysis of OnabotulinumtoxinA in chronic migraine post-NICE UK technology appraisal.
11. Physical activity guidelines: UK Chief Medical Officers' report.
12. UK Chief Medical Officers' physical activity guidelines (full text).
13. Physical activity guidelines for adults aged 19 to 64.
14. Topiramate (Topamax): introduction of new safety measures including a Pregnancy Prevention Programme.
15. Topiramate Pregnancy Prevention Programme (Risk Minimisation Material).
16. Resmetirom (Rezdiffra) authorised to treat metabolic dysfunction-associated steatohepatitis (MASH) in adults.
17. Mediterranean ketogenic diet accounts for reduced pain in migraine (Olivito I et al.).
18. Food in Migraine Management: Dietary Interventions in the Pathophysiology and Prevention of Headaches – A Narrative Review. Nutrients..
19. AA in Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)/NAFLD. Reviews of Physiology, Biochemistry and Pharmacology..
20. Immunity as Cornerstone of Non-alcoholic Fatty Liver Disease: Innate and Adaptive Immune Mechanisms in Metabolic Syndrome-related Steatohepatitis. Iranian Journal of Allergy, Asthma, and Immunology..
21. Acupuncture modulates migraine-related neural and neuroendocrine regulatory pathways. The Journal of Headache and Pain..
22. The role of non-coding RNAs in the pathogenesis of migraine: from molecular insights to potential biomarkers. Frontiers in Neurology..
23. Improvement in histological endpoints of MAFLD following a 12-week aerobic exercise intervention. Alimentary Pharmacology & Therapeutics..

Frequently Asked Questions